期刊文献+

HPLC法测定胎盘灌流液中安替比林浓度 被引量:2

Determination of the Concentration of Antipyrine in Placental Perfusion by HPLC
原文传递
导出
摘要 目的:建立测定胎盘灌流液中安替比林浓度的方法。方法:样品采用液-液萃取预处理后,以高效液相色谱法测定。色谱柱为WatersSymmetryC18,流动相为甲醇∶0.05mol·L-1磷酸氢二钠缓冲液(pH=6.5)=70∶30,内标为非那西丁,流速为1mL·min-1,紫外检测波长为254nm。结果:安替比林检测浓度在1.095~20mg·L-1范围内线性关系良好(r=0.9996);低、中、高3种浓度质控样品的日内RSD分别为5.03%、1.49%、1.53%,日间RSD分别为2.99%、1.01%、0.75%;平均方法回收率为97.19%~103.11%。结论:本方法简便可靠、专属性好、精密度高,可用于胎盘灌流液中安替比林浓度的测定。 OBJECTIVE: To establish the HPLC method for the concentration determination of antipyrine in placental perfusion. METHODS: The determination was performed on Waters Symmetry Ct8 column with mobile phase consisted of methanol-0.05 mol. L-1 phosphate buffer (pH6.5)(70:30) at the flow rate of 1 mL. min-1 using phenacetin as internal standard. The UV detection wavelength was at 254 mn. The concentration of antipyrine in placental perfusion was determined by liquid-liquid extraction pre-treatment. RESULTS: The linear range of antipyrine was 1.095~20 mg.L -1 (r=0.999 6). The intra-day RSD of quality control were 5.03%, 1.49% and 1.53% ; the intar-day RSD of quality control were 2.99%, 1.01% and 0.75% for three concentrations of antipyrine. The average recoveries were 97.19% ~ 103.11%. CONCLUSION: The method is simple, reliable, specific and precise. It is suitable for determination of antipyrine in placental perfusion.
出处 《中国药房》 CAS CSCD 2012年第10期884-886,共3页 China Pharmacy
基金 云南省应用基础研究面上项目(2008ZC128M)
关键词 安替比林 高效液相色谱法 胎盘 灌流 Antipyrine HPLC Placenta Perfusion
  • 相关文献

参考文献9

  • 1Myren M, Mose T, Mathiesen L, et al. The human pla- centa an alternative for studying foetal exposure[J].Toxi- col I8tro,2007,21(7) : 1 332.
  • 2Balakrishnan B, Henare K, Thorstensen EB, et al. Trans- fer of bisphenol A across the human placenta[J]. Am J Ob- stet Gynecol,2010,202 (4) : 393.
  • 3Balakrishnan B, Thorstensen EB, Ponnampalam AP, et al. Transplacental transfer and biotransformation of genistein in human placenta[J]. Placenta, 2010,31 (6) : 506.
  • 4Mathiesen L, Mose T, Morck T J, et al. Quality assess- ment of a placental perfusion protocol [J]. Reproductive Toxicology, 2010,30( 1 ) : 138.
  • 5Shintaku K, Arima Y, Dan Y, et al. Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflam- matory drug, across human placenta[J]. Drug Metabolism and Disposition, 2007,35 (5) : 772.
  • 6Nemmar A, Hamoir J, Nemery B, et al. Evaluation of par- ticle translocation across the alveolo-capillary barrier in isolated perfused rabbit lung model[J]. Toxicology, 2005, 208(1):105.
  • 7Gedeon C, Behravan J, Koren G. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure[J]. Placenta, 2006,27 ( 11 ) : 1 092.
  • 8Line M, Erik R, Tina M, et al. Transport of benzo[a]py- rene in the dually perfused human placenta perfusion mod- el: effect of albumin in the perfusion medium[J]. Basic & Clinical Pharmacology & Toxicology, 2009,105 (3) : 181.
  • 9Myllynen PK, Pienimaki PK, Vahakangas KH. Transpla- cental passage of lamotrigine in a human placental perfu- sion system in vitro and in maternal and cord blood in vi- vo [J]. Eur J Clin Pharmacol, 2003,58 (10) : 677.

同被引文献31

  • 1PANIGEL M, PASCAUD M, BRUNJ L. Radioangiographic study of circulation in the villi and intervillous space of isolated human placental cotyledon kept viable by perfusion[J].Journal De Physiologie, 1967 ,59 (1 suppl) : 277 .
  • 2HUTSONJ R, GARCIA-BOURNISSEN F, DAVIS A, et al. The human placental perfusion model: A systematic review and devel?opment of a model to predict in vivo transfer of therapeutic drugs[J] . Clin Phannacol Ther ,2011,90(1 ) :67-76.
  • 3MYREN M,MOSE T,MATHIESEN L,et al. The human placen?ta-An alternative for studying foetal exposure[J]. Toxicol in Vitro,2007 ,21 (7) : 1332-1340.
  • 4MATHIESEN L, MOSE T, MOReK TJ, et al. Quality assessment of a placental perfusion protocol[J]. Reprod Toxicol, 2010,30 (1) : 138-146.
  • 5MATHIESEN L,RYTTING E,MOSE T,et al. Transport of benzo[at] pyrene in the dually perfused human placenta perfusion mod?el: Effect of albumin in the perfusion medium[J]. Basic Clin Pharmacol ,2009,105 (3) : 181-187.
  • 6BERVEILLER P, MIR 0, VINOT C ,et al. Transplacental transfer of oseltamivir and its metabolite using the human perfused placen?tal cotyledon model[J] . AmJ Obstet Gynecol, 2012 , 206 ( I ) : 92el-92e6.
  • 7HNAT M,BAWDON R E. Transfer of meropenem in the ex vivo human placenta perfusion model[J]. Infect Dis Obstet Gynecol, 2005,13 (4) :223-227.
  • 8NANOVSKAYA T N, PATRIKEEVA S, HE MAUER S, et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide[J] .J Matern-Fetal Neo M, 2008,21 (3) : 197-207.
  • 9KRAEMERJ , KLEINJ, LUBETSKY A, et al. Perfusion studies of glyburide transfer across the human placenta: Implications for fe?tal safety[J].AmJ Obstet Gynecol,2006,195(1) :270-274.
  • 10HOLMES HJ, CASEY B M, BA WDON R E. Placental transfer of rosiglitazone in the ex vivo human perfusion model[J] . AmJ Ob?stet Gynecol,2006,195(6) :1715-1719.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部